We prospectively recruited 171 tumor patients who received anti-tumor chemotherapy combined with (n = 83) or without (n = 88) anti-PD-1 treatment at SAHZU between 16th Sep 2022 and 24th Feb 2023 (Supplementary information, Fig. S11g). The gene discussed is PDCD1; the disease is neoplasm.